LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 8 of 15: Cell count and normalized growth rate inhibition values within biological replicate 1. - Dataset (ID:20245)
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Replicate | Assay Well | Timepoint | Timepoint Unit | Total Cell Count Before Treatment | Total Cell Count After Treatment | Total Control Cell Count | Relative Cell Count | Normalized Growth Rate Inhibition Value |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
MCF 10A | XMD16-144 | 0.37 | uM | LJP5 | 3 | M10 | 72 | hr | 513 | 1347 | 10483 | 0.1285 | 0.2481 |
MCF 10A | XMD16-144 | 1.11 | uM | LJP5 | 1 | M09 | 72 | hr | 513 | 1177 | 10254 | 0.1148 | 0.2117 |
MCF 10A | XMD16-144 | 1.11 | uM | LJP5 | 2 | M09 | 72 | hr | 513 | 1437 | 10349 | 0.1389 | 0.2681 |
MCF 10A | XMD16-144 | 1.11 | uM | LJP5 | 3 | M09 | 72 | hr | 513 | 1295 | 10483 | 0.1235 | 0.2369 |
MCF 10A | XMD16-144 | 3.33 | uM | LJP5 | 1 | M08 | 72 | hr | 513 | 1406 | 10254 | 0.1371 | 0.2627 |
MCF 10A | XMD16-144 | 3.33 | uM | LJP5 | 2 | M08 | 72 | hr | 513 | 1353 | 10349 | 0.1307 | 0.2506 |
MCF 10A | XMD16-144 | 3.33 | uM | LJP5 | 3 | M08 | 72 | hr | 513 | 1133 | 10483 | 0.1081 | 0.1995 |
MCF 10A | XMD16-144 | 10 | uM | LJP5 | 1 | M07 | 72 | hr | 513 | 562 | 10254 | 0.0548 | 0.0212 |
MCF 10A | XMD16-144 | 10 | uM | LJP5 | 2 | M07 | 72 | hr | 513 | 791 | 10349 | 0.0764 | 0.1049 |
MCF 10A | XMD16-144 | 10 | uM | LJP5 | 3 | M07 | 72 | hr | 513 | 594 | 10483 | 0.0567 | 0.0341 |
MCF 10A | Erlotinib | 0.04 | uM | LJP5 | 1 | M24 | 72 | hr | 513 | 9864 | 10254 | 0.9619 | 0.9821 |
MCF 10A | Erlotinib | 0.04 | uM | LJP5 | 2 | M24 | 72 | hr | 513 | 9672 | 10349 | 0.9345 | 0.9690 |
MCF 10A | Erlotinib | 0.04 | uM | LJP5 | 3 | M24 | 72 | hr | 513 | 10242 | 10483 | 0.9770 | 0.9893 |
MCF 10A | Erlotinib | 0.12 | uM | LJP5 | 1 | M23 | 72 | hr | 513 | 8565 | 10254 | 0.8352 | 0.9184 |
MCF 10A | Erlotinib | 0.12 | uM | LJP5 | 2 | M23 | 72 | hr | 513 | 8748 | 10349 | 0.8453 | 0.9239 |
MCF 10A | Erlotinib | 0.12 | uM | LJP5 | 3 | M23 | 72 | hr | 513 | 8522 | 10483 | 0.8129 | 0.9070 |
MCF 10A | Erlotinib | 0.37 | uM | LJP5 | 1 | M22 | 72 | hr | 513 | 2292 | 10254 | 0.2235 | 0.4139 |
MCF 10A | Erlotinib | 0.37 | uM | LJP5 | 2 | M22 | 72 | hr | 513 | 2089 | 10349 | 0.2018 | 0.3825 |
MCF 10A | Erlotinib | 0.37 | uM | LJP5 | 3 | M22 | 72 | hr | 513 | 2690 | 10483 | 0.2566 | 0.4631 |
MCF 10A | Erlotinib | 1.11 | uM | LJP5 | 1 | M21 | 72 | hr | 513 | 591 | 10254 | 0.0576 | 0.0331 |
MCF 10A | Erlotinib | 1.11 | uM | LJP5 | 2 | M21 | 72 | hr | 513 | 667 | 10349 | 0.0644 | 0.0623 |
MCF 10A | Erlotinib | 1.11 | uM | LJP5 | 3 | M21 | 72 | hr | 513 | 620 | 10483 | 0.0591 | 0.0443 |
MCF 10A | Erlotinib | 3.33 | uM | LJP5 | 1 | M20 | 72 | hr | 513 | 616 | 10254 | 0.0601 | 0.0431 |
MCF 10A | Erlotinib | 3.33 | uM | LJP5 | 2 | M20 | 72 | hr | 513 | 697 | 10349 | 0.0673 | 0.0731 |
MCF 10A | Erlotinib | 3.33 | uM | LJP5 | 3 | M20 | 72 | hr | 513 | 688 | 10483 | 0.0656 | 0.0696 |